45,129CONSOLIDATED NET INCOME
32,686Less: Net income attributable to noncontrolling interests
—(12,508)NET INCOME ATTRIBUTABLE TO ENDO PHARMACEUTICALS HOLDINGS INC.$
20,178DILUTED EARNINGS PER SHARE
.00DILUTED WEIGHTED AVERAGE SHARES
Notes to reconciliation of our GAAP statements of operations to our adjusted statements of operations:
To exclude amortization of commercial intangible assets related to marketed products of $37,211 and the impact of inventory step-up recorded as part of acquisition accounting of $13,786.
To exclude certain costs and separation benefits incurred in connection with continued efforts to enhance the Company's operations.
To exclude milestone and upfront payments to partners.
To exclude acquisition-related costs of $6,758 as well as the impact, under purchasing accounting, of a gain recorded to reflect the change in the company's current estimate of fair value, in accordance with GAAP, of the contingent consideration associated with the Indevus and Qualitest acquisitions of $(685).
To exclude additional interest expense as a result of adopting ASC 470-20.
To reflect the cash tax savings resulting from the Indevus, HealthTronics, Penwest and Qualitest acquisitions and the tax effect of the pre-tax adjustments above at applicable tax rates.
See Endo's Current Report on Form 8-K filed today with the Securities and Exchange Commission for additional non-GAAP reconciliations and for an explanation of Endo's reasons for using non-GAAP measures.Reconciliation of Projected GAAP Diluted Earnings Per Share to Adjusted Diluted Earnings Per Share Guidance for 2012Year EndingDecember 31, 2012Projected GAAP dilu
Copyright©2010 PR Newswire.
All rights reserved